Recursion Pharmaceuticals (RXRX) Asset Writedowns and Impairment (2022 - 2025)
Recursion Pharmaceuticals' (RXRX) quarterly Asset Writedowns and Impairment came in at $6.0 million in Q1 2025, up 5414.81% YoY from $108000.0 in Q1 2024, and up 5414.81% on a QoQ basis from $108000.0 in Q1 2024.
Recursion Pharmaceuticals (RXRX) Asset Writedowns and Impairment (2022 - 2025) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 4 years of Asset Writedowns and Impairment data on file, last reported at $6.0 million in Q1 2025.
- Quarterly Asset Writedowns and Impairment rose 5414.81% year-over-year to $6.0 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $6.0 million (up 5414.81% YoY) and the FY2025 annual result came in at $6.0 million, up 5414.81% from the prior year.
- Asset Writedowns and Impairment rose to $6.0 million in Q1 2025, from $108000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $6.0 million in Q1 2025 to a low of $19000.0 in Q3 2023.
- A 4-year average of $2.0 million and a median of $1.2 million in 2023 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2024 — Asset Writedowns and Impairment plunged 90.76% — and 2025, when it soared 5414.81%.
- Tracing RXRX's Asset Writedowns and Impairment over 4 years: stood at $2.8 million in 2022, then sank by 99.32% to $19000.0 in 2023, then surged by 468.42% to $108000.0 in 2024, then surged by 5414.81% to $6.0 million in 2025.
- The last three Asset Writedowns and Impairment figures came in at $6.0 million (Q1 2025), $108000.0 (Q1 2024), and $19000.0 (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 5.96 Mn |
| Mar 31, 2025 | 5.96 Mn |
| Mar 31, 2024 | 108,000.00 |
| Mar 31, 2024 | 108,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Mar 31, 2023 | 1.17 Mn |
| Mar 31, 2023 | 1.17 Mn |
| Jun 30, 2022 | 2.81 Mn |
| Jun 30, 2022 | 2.81 Mn |